ArticleHuman vaccines & immunotherapeutics2025
Cost-effectiveness and epidemiological impact of gender-neutral vaccination against human papillomavirus in economically developed metropolises of Beijing, Shanghai, and Guangzhou, China.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Geographic and temporal variations in cancer incidence attributable to human papillomavirus infection in China: a population-based study.BMC public health · 2026Article
- Cost-effectiveness and health impact of gender-neutral and single-dose HPV vaccination in Hong Kong: a modeling analysis.The Lancet regional health. Western Pacific · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) causes multiple diseases in both sexes. This study evaluates the cost-effectiveness and epidemiological impact - defined as reductions in HPV-related disease cases - of a gender-neutral vaccination (GNV) strategy in China's economically developed metropolises: Beijing, Shanghai, and Guangzhou. A discrete-time Markov model simulated no vaccination, female-only vaccination (FOV), and GNV strategies among 12-year-olds. The cost matrix included vaccine procurement, administration, and treatment costs from Chinese data and literature. The case matrix translated model-estimated reductions in HPV infections into decreases in disease incidence by applying baseline incidence rates adjusted for HPV genotype attribution, relative risk reductions, and disease-specific lag times. Outcomes assessed were costs (2023 USD), quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs), and cases averted. Compared to FOV, the ICERs for GNV were USD 323,134/QALY (Beijing), USD 305,816/QALY (Shanghai), and USD 251,853/QALY (Guangzhou), exceeding local willingness-to-pay thresholds, indicating cost-ineffectiveness. The GNV strategy averted 3.9%, 4.7%, and 3.9% more HPV-related cases over 30 years in Beijing, Shanghai, and Guangzhou, respectively. Sensitivity analyses showed that GNV became cost-effective when the 9vHPV uptake rate was below 20% in girls (Shanghai) or below 10% in girls (Beijing and Guangzhou), regardless of the uptake rate (≤80%) in boys. It was also cost-effective if vaccine price dropped to USD 21.4 (Shanghai), USD 18.9 (Beijing), or USD 19.1 (Guangzhou). Price thresholds rose substantially with decreasing female uptake but changed little with male uptake variation. The GNV strategy may be cost-effective when the 9vHPV uptake rate remains low in girls or the vaccine price significantly decreases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.